Patents Assigned to School Corporation, Azabu Veterinary Medicine Educational Institution
  • Publication number: 20240000858
    Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
    Type: Application
    Filed: December 20, 2022
    Publication date: January 4, 2024
    Applicants: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
  • Patent number: 11826424
    Abstract: Strains of human-derived bacteria have been obtained from complex fecal samples and shown to induce accumulation of Th17 cells in the intestine and promote immune functions. Pharmaceutical compositions containing these bacteria can be used as anti-infectives and as adjuvants in mucosal vaccines.
    Type: Grant
    Filed: May 14, 2021
    Date of Patent: November 28, 2023
    Assignees: RIKEN, The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Masahira Hattori, Hidetoshi Morita
  • Publication number: 20230213511
    Abstract: There are provided a method and a kit for evaluating allergen inactivators, the method and kit making it possible to carry out a precise and reproducible evaluation irrespective of the type of test drug, or the type of accompanying components thereof, that is subject to the evaluation.
    Type: Application
    Filed: April 23, 2021
    Publication date: July 6, 2023
    Applicants: SCHOOL CORPORATION, AZABU VETERINARY MEDICINE EDUCATIONAL INSTITUTION, ITEA INC
    Inventors: Masahiro SAKAGUCHI, Jumpei UCHIYAMA, Megumi YOSHIDA, Keijiro MIZUKAMI, Keigo MIZUKAMI, Keigo KURATA
  • Publication number: 20230119232
    Abstract: The present invention is intended to provide a lactic acid bacterium-containing composition that is effective for suppression of the onset of allergies. More specifically, the present invention relates to a composition comprising lactic acid bacteria belonging to Lactobacillus animalis, wherein the composition is provided in the form of, for example, a food or beverage composition, a pharmaceutical composition, a feed composition, a sanitary composition or the like. Furthermore, the present invention provides a method for preventing the onset of allergies.
    Type: Application
    Filed: March 5, 2021
    Publication date: April 20, 2023
    Applicants: SCHOOL CORPORATION, AZABU VETERINARY MEDICINE EDUCATIONAL INSTITUTION, ITEA INC.
    Inventors: Masahiro SAKAGUCHI, Jumpei UCHIYAMA, Tomoki FUKUYAMA
  • Patent number: 11547732
    Abstract: Provided herein are methods of treating graft-versus-host disease in a subject by administering pharmaceutical compositions containing bacterial strains of the Clostridia class. Also described herein are exemplary human-derived bacteria belonging to the Clostridia class, combinations of which have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions, and are therefore useful for mitigating pathological immune responses. Pharmaceutical compositions containing these and/or related bacteria can be used to prevent and treat immune-mediated diseases such as graft-versus-host disease.
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: January 10, 2023
    Assignees: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
  • Publication number: 20220072125
    Abstract: Strains of human-derived bacteria have been obtained from complex fecal samples and shown to induce accumulation of Th17 cells in the intestine and promote immune functions. Pharmaceutical compositions containing these bacteria can be used as anti-infectives and as adjuvants in mucosal vaccines.
    Type: Application
    Filed: May 14, 2021
    Publication date: March 10, 2022
    Applicants: RIKEN, The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Masahira Hattori, Hidetoshi Morita
  • Publication number: 20210393660
    Abstract: There is provided with a method of treating cancer. A set of administration of a compound represented by General Formula (I) or a pharmaceutically acceptable salt thereof to a patient, at a dose such that 8 mg/kg or less of the compound represented by General Formula (I) is administered, and irradiation to the patient immediately following the administration is repeated. A total dosage of the irradiation to a cancer is 10 Gy or more.
    Type: Application
    Filed: September 3, 2021
    Publication date: December 23, 2021
    Applicants: M.T.3, Inc., NIHON UNIVERSITY, SCHOOL CORPORATION, AZABU VETERINARY MEDICINE EDUCATIONAL INSTITUTION
    Inventors: Hiroeki SAHARA, Tomohiro NAKAYAMA, Takuya MARUO
  • Publication number: 20210386783
    Abstract: The prevent invention provides an activated T cell in which the expression of an immune checkpoint molecule is suppressed, a method for producing the T cell, and a method for screening for a substance that can be used in the production of the T cell. Specifically, the prevent invention includes, as solving means, a method for producing or inducing a T cell in which the expression of an immune checkpoint molecule is not induced, the method comprising reducing or losing the function of UDP-glucose ceramide glucosyltransferase (UGCG) or ganglioside in a T cell, and a T cell produced or induced by the aforementioned method.
    Type: Application
    Filed: October 24, 2019
    Publication date: December 16, 2021
    Applicants: SCHOOL CORPORATION, AZABU VETERINARY MEDICINE EDUCATIONAL INSTITUTION, TELLA, INC.
    Inventors: Tadashi YAMASHITA, Masaki NAGANE, Teruo IKEDA, Shoichiro MIYATAKE, Mariko OKAMOTO
  • Publication number: 20210137998
    Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
    Type: Application
    Filed: October 15, 2020
    Publication date: May 13, 2021
    Applicants: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
  • Patent number: 10835559
    Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: November 17, 2020
    Assignees: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
  • Patent number: 10624933
    Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: April 21, 2020
    Assignees: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
  • Publication number: 20190314426
    Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
    Type: Application
    Filed: May 31, 2019
    Publication date: October 17, 2019
    Applicants: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
  • Publication number: 20190290753
    Abstract: Strains of human-derived bacteria have been obtained from complex fecal samples and shown to induce accumulation of Th17 cells in the intestine and promote immune functions. Pharmaceutical compositions containing these bacteria can be used as anti-infectives and as adjuvants in mucosal vaccines.
    Type: Application
    Filed: April 5, 2019
    Publication date: September 26, 2019
    Applicants: Riken, The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Masahira Hattori, Hidetoshi Morita
  • Patent number: 10342832
    Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: July 9, 2019
    Assignees: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
  • Patent number: 10300137
    Abstract: Strains of human-derived bacteria have been obtained from complex fecal samples and shown to induce accumulation of Th17 cells in the intestine and promote immune functions. Pharmaceutical compositions containing these bacteria can be used as anti-infectives and as adjuvants in mucosal vaccines.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: May 28, 2019
    Assignees: RIKEN, The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Masahira Hattori, Hidetoshi Morita
  • Patent number: 10238694
    Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: March 26, 2019
    Assignees: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
  • Publication number: 20190046591
    Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
    Type: Application
    Filed: October 25, 2018
    Publication date: February 14, 2019
    Applicants: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
  • Publication number: 20190030092
    Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
    Type: Application
    Filed: October 15, 2018
    Publication date: January 31, 2019
    Applicants: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
  • Patent number: 10183045
    Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: January 22, 2019
    Assignees: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
  • Publication number: 20180243348
    Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
    Type: Application
    Filed: April 27, 2018
    Publication date: August 30, 2018
    Applicants: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita